Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 918 clinical trials
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors.

refractory malignant solid neoplasm
orchiectomy
antibody therapy
fancc
baf250a
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

ffpe
seribantumab
solid tumor
blood transfusion
platelet count
  • 0 views
  • 19 Feb, 2024
  • 1 location
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

solid neoplasm
treatment regimen
solid tumour
  • 0 views
  • 19 Feb, 2024
  • 1 location
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

measurable disease
advanced malignant solid tumor
HER2
solid tumor
gastric tumor
  • 0 views
  • 19 Feb, 2024
  • 7 locations
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

oophorectomy
hysterectomy
measurable disease
bilateral oophorectomy
systemic therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

steroid therapy
cytokine release syndrome
biologic therapy
antibody therapy
stem cell infusion
  • 0 views
  • 19 Feb, 2024
  • 1 location
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

pd-l1
immunomodulators
transitional cell carcinoma
advanced renal cell carcinoma
kidney function tests
  • 0 views
  • 19 Feb, 2024
  • 1 location
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with BAY1895344 in combination with niraparib. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with niraparib, how the drug is tolerated and …

peritoneal cancer
measurable disease
niraparib
platelet count
muga scan
  • 0 views
  • 19 Feb, 2024
  • 4 locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations.

genetic alteration
antibody therapy
rhabdomyosarcoma recurrent
corticosteroids
cancer treatment
  • 0 views
  • 19 Feb, 2024
  • 83 locations
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location